Member Info for Retireby40

CV will continue I mean.

I’m not expecting an RNS tomorrow but your logic doesn’t work. I doubt the team will down tools because it’s Easter. I imagine CE will continue over any weekend, it’s pretty important!

It’d be very odd for the gov to want us to self-administer Innova’s test given what’s involved whereas our Anterior nasal test a lot less painful and easy to get right. The results of self-administering Innova’s test would be questionable as tricky to get the right spot as it were.

If we don’t get an RNS tomo no cause for concern as I’m sure CV and CE not far away and a gold standard and easy to administer test will win hands down.

I am sure AVCT will be part of this but we are initially going for professional use and self-administered will follow so people need to temper their expectations for this week. Getting golf standard CV is the key and the rest will take care of itself.

I think this is great as illustrates delivery mechanism key and doing direct to the lung the way forward. Good for SNG.

India reports national record 103,558 new Covid cases in 24 hours

I almost think sod the UK quite frankly and I’m sure the US et al. will take all the courses we can produce. Many hospitals will be stockpiling and I’m sure we’ll sell what we can produce. Assuming we don’t get bought beforehand.

I gave up my job of 14 years 3 years ago (as it happens just before my 40th) to travel and take a year off I haven’t gone back to work yet. Luckily built a decent holding in 4 PLCs that have all multi-bagged (except one but am circa 65% up in that) and am hoping good news here and in SNG in the near term makes that a reality! We’ll see.

Clearly hoping CV as good as initial data and the covid LFT can fund the therapeutics and other tests even. Hope AVA6000 gets in the clinic this summer too as that excites me most.

Happy Easter all.

Indeed Jaylarc. This was from the 16 Feb RNS - Importantly, out of a total of 26 negative samples tested with the lateral flow device, the test correctly identified all 26 as negative, giving a clinical specificity of 100%. High specificity is critical for a lateral flow test for mass screening so that large numbers of false positives are not generated which would create a major burden on follow-on testing resources, and result in a significant socio-economic cost of unnecessarily isolating people.

Ah, I was wrongly working to around 65 days (54 days like last time plus 20% for additional patients). The good news if you’re right which seems likely is I’ll be able to load up my ISA with more shares. Another month or so won’t hurt. Ideally we’ll get positive ACTIV-2 news after shares bedded followed my fantastic hone trial results and EUA.

To be fair it doesn’t matter and best to exceed expectations.

It’s great we’re increasing manufacturing in China too, cheaper to manufacture, it’s our largest market and good to employ more people there as good for business.

So much going on and I’m sure Q2 will be better for RNSs and I’m sure the re-rate will be in fill flow.

The Q&A is superb BTW

If our aggregated income was £6.1m and MWG has pretty much doubled (£3.65m) and we are again seeing treble digit growth why is the forecast £10m? We are currently forecasting growth of 65% so not triple digit.

From the Q&A -
Our business model is based on the generation of recurring revenues across all divisions, moving from an equipment sales model. We have not yet established which divisions will be higher or lower than the others as all are growing at triple-digit percentage growth and it will take another year to fully assess

So surely it’s safe to assume it was a buy and an entity with less than 0.5% of shares before buy. Bodes well.

Really underlines the massive potential here. I’m sitting on my holding for a good while yet and the issue I think will be managing demand.

Although GB has his faults (as we all do!) with twitter and possibly sometimes not punchy enough in presentations I can’t moan about his vision and pedigree in turning businesses around. Have been here for a couple of years I believe and believe the foundations have been laid and now for more growth!

Great to hear if further cash is required (doubt it) but if so we have access to finance rather than dilution.

Potential here is massive snd massively undervalued given the IP and data alone.

Muggins get a life.

Remember you said you were wanting to see more MWG sales? Last year revenue was £1.7m and this year we have £3.65m in orders and a similar sales pipeline. Hats off.

I imagine they’ll upgrade forecast once they have confirmed orders.

A solid interview which gives me renewed confidence. Onwards and upwards.

I compare with Alastair at Avacta as just over a year ago its market cap was similar to ours and now it’s some £600m and he doesn’t look out of place and has attracted heavyweight investors. Yes their platforms and IP helps but heavyweights investors also invest in the leader of a co. I’m not saying GB won’t attract them I’m just not sure. I hope he’s the man to take us to the next level.

Agree toon. I find it odd they seemingly ignore PD which they should be shouting from the rooftops about.

Subject to completion of additional human trials, the Microtox(R) BT would be expected to meet the criteria for UK, MHRA's Target Product Profile Rapid Breath Test which would enable us to roll out the COVID19 and other pathogen breath tests later this year.

What about PD for ****s sake!

Also, £6.1m aggregated revenue last year means forecast is 65% growth so not treble digit as GB said and with £2.4m in Q4 and with £3.6m MWG we are seemingly going backwards?

They said they’ve launched skintrustclub app but I can’t find it, can anyone else?

Another damp squib IMO and I shouldn’t have expected more. Massive potential that’s clear but I’m not convinced GB is the person to take us to £100m+ market cap. I like him and his vision but being CEO of a £10m-£50m market cap co is all well and good but going to £100m+ and attracting different investor profile requires a different skill set. Alastair Smith at Avacta for example has missed targets but exudes confidence and articulates the plan and their complex platforms superbly whereas GB spends most of the time pumping on twitter and delivering woolly RNSs that don’t live up to the hype.

No mention of multi-million £ contracts, what about PD, is skintrustclub actually launched (app?) and why tell us 30 March last year we had £2m orders and not do the same this year when we have a webinar? Yet again too many questions after an RNS.